We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New RT-LAMP Assay Offers Affordable and Reliable Pathogen Detection for Resource-Limited Settings

By LabMedica International staff writers
Posted on 15 Jul 2025

The high cost and logistical complexities associated with rapid, point-of-care tests have long hampered widespread access to molecular diagnostics, especially in low- and middle-income countries. More...

In these settings, the need for accurate and affordable pathogen detection is particularly pressing, especially during outbreaks. Traditional diagnostic methods often rely on expensive tests, require cold chains for transport and storage, and demand sophisticated laboratory setups, making them difficult to deploy in resource-limited environments. Researchers have now developed a new, more affordable solution aimed at addressing these issues, making molecular diagnostics more accessible and feasible in underserved areas.

A team from the Vienna BioCenter (Vienna, Austria) and the West African Center for Cell Biology of Infectious Pathogens (WACCBIP) at the University of Ghana (Accra, Ghana) has developed a lyophilized open-source reverse transcription loop-mediated isothermal amplification (RT-LAMP) assay for pathogen detection. This assay uses non-proprietary enzymes, including reverse transcriptase, DNA polymerase, and uracil DNA glycosylase, to reduce reliance on expensive commercial solutions. The assay is both heat-stable and robust, making it possible to store and transport the diagnostic tools at ambient or elevated temperatures, bypassing the need for cold chains. The RT-LAMP assay is adaptable for rapid detection of various pathogens and can be used with swab or gargle samples, demonstrating high sensitivity and providing a colorimetric result. The open-source nature of the assay means that the enzyme mixture can be self-produced, further driving down costs and improving accessibility.

The assay was tested in a proof-of-concept study with lyophilized RT-LAMP reaction mixes shipped to Ghana, where it showed performance comparable to results obtained in Vienna. This study, published in Life Science Alliance, demonstrated that the assay is both robust and suitable for field implementation across diverse settings. The researchers envision multiple models for implementation, ranging from centralized production to decentralized in-lab preparation. The team is working to make the assay more widely accessible, having deposited essential vectors and providing protocols for protein expression and purification on publicly accessible platforms. Moving forward, the researchers plan to further validate the system's performance across a broader range of pathogens and settings.

“By making reliable pathogen detection both affordable and independent of complex logistics like cold chains, our protocols empower laboratories and public health institutions worldwide to take control of their diagnostic capabilities, especially during outbreaks,” said co-first author Martin Matl, PhD.

Related Links:
Vienna BioCenter
WACCBIP


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Pan-Cancer Panel
TruSight Oncology 500
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.